DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions
and services to the pharmaceutical, biotechnology and medical device
industries, today announced the appointment of Dr. James Cummings as
President of ClinicalRM. ClinicalRM is a wholly owned subsidiary of ICON
plc, providing full service and functional research solutions to a range
of U.S. Federal Health Agencies.
Dr. Cummings has over 20 years' experience within the global health and
government research and development industries. He is a vaccine and
infectious disease specialist and most recently led the Influenza
related program at Novavax, Inc, in his role as VP Clinical Development
and Translational Medicine. Dr. Cummings is a retired Colonel with the
US Army and served as Director of the Department of Defence's Global
Emerging Infectious Surveillance and Response System (GEIS) and as the
Director of Translational Medicine & Regulated Activities for the Walter
Reed Army Institute of Research (WRAIR).
Dr. Cummings is replacing ClinicalRM founder and CEO, Victoria Tifft,
who will transition her leadership role throughout Q1 2018 and will move
to the ClinicalRM Board as a non-executive Director in February 2018.
Dr. Cummings will work closely with the ClinicalRM Board, Executive Team
and ICON Leadership in the continued development of the ClinicalRM
organisation as the CRO of choice in the government sponsored research
sector.
Commenting on the appointment of Dr. Cummings, Colin Stanley, President,
ICON Functional Services, said: "I am pleased that James has joined
ClinicalRM to lead the company's next stage of development and that
Vicki will continue to provide guidance as a valuable member of the
ClinicalRM Board. James' knowledge of the industry, operational
experience and understanding of research will help ICON expand in the
government research sector. Furthermore his expertise will strengthen
ICON's capabilities in vaccines and infectious disease, both of which
are important areas of focus for government and commercial customers."
Dr. Cummings commented: "I am excited to take on this unique challenge
to combine ClinicalRM's extensive sector experience and reputation, with
ICON's broad, global capabilities to provide a differentiated service
offering to federal health agencies. I look forward to working with
Vicki, the ClinicalRM Board and the wider ICON team to broaden and
deepen our relationships with federal and commercial research sponsors."
About ClinicalRM
ClinicalRM, a wholly-owned subsidiary of ICON plc, is a full-service CRO
providing clinical trial and functional services to government and
commercial customers. From international partnerships and affiliations
to government relations and local alliances, ClinicalRM delivers
projects spanning the government, academic and commercial marketplaces.
The company has a distinct ability to provide boots-on-the-ground and
rapid response efforts to global health crises. More information is at http://www.clinicalrm.com/
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 97 locations in 38 countries and
has approximately 13,100 employees. More information is at http://www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-G
View source version on businesswire.com: http://www.businesswire.com/news/home/20180109005846/en/
ICON Media Contact
Olivia Pimenta
Weber Shandwick
+44
(0)207 067 0557
OPimenta@webershandwick.com
Source: ICON plc
News Provided by Acquire Media
